KH617 / Chengdu Kanghong Pharma - LARVOL DELTA

A phase I study to assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood) (ESMO 2025) - P1 | "Conclusions KH617 exhibits a favorable safety profile and preliminary evidence of anti-tumor activity, particularly in patients with recurrent gliomas. The results support further development of KH617."

Clinical • Metastases • P1 data • PK/PD data • Brain Cancer • Glioblastoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Phase 2 Clinical Trial of KH617 (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Sichuan Honghe Biotechnology Co., Ltd.

Monotherapy • New P2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

The natural compound KH617 targets pediatric and adult high-grade gliomas (AACR 2025) - "Integrating robust preclinical data and encouraging early clinical outcomes, KH617 emerges as a promising therapeutic candidate for pediatric and adult HGGs, addressing critical unmet needs in neuro-oncology.Keywords:KH617; Temozolomide; Avastin; Radiation; High-grade gliomas"

Clinical • Late-breaking abstract • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor

Phase 1 Trial of KH617 (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Sichuan Honghe Biotechnology Co., Ltd. | Initiation date: Dec 2023 ➔ Dec 2022

Metastases • Trial initiation date • Oncology • Solid Tumor

Phase 1 Trial of KH617 (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Sichuan Honghe Biotechnology Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor